REFERENCES
- Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum
2020. Am J Kidney Dis. 2020; 75(1): 124-137.
- Haris Á, Dolgos S, Polner K. Therapy and prognosis of ANCA-associated
vasculitis from the clinical nephrologist’s perspective. Int
Urol Nephrol. 2017; 49(1): 91-102.
- Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations
for the management of ANCA-associated vasculitis. Ann Rheum
Dis. 2016; 75(9): 1583-1594.
- Jones RB, Hiemstra TF, Ballarin J, et al. European Vasculitis Study
Group (EUVAS): Mycophenolate mofetil versus cyclophosphamide for
remission induction in ANCA-associated vasculitis: a randomised,
non-inferiority trial. Ann Rheum Dis. 2019; 78(3): 399-405.
- Moiseev SV, Smitienko I, Bulanov N, et al. Changing landscape of
immunosuppression in ANCA-associated vasculitis. Ann Rheum Dis79: e59, 2020
- Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic
acid: An Update. Clin Pharmacokinet. 2018; 57(5): 547-558.
- Joy MS, Hilliard T, Hu Y, et al. Influence of clinical and demographic
variables on mycophenolic acid pharmacokinetics in antineutrophil
cytoplasmic antibody-associated vasculitis. Ann Pharmacother.2009; 43(6): 1020-1027.
- Schaier M, Scholl C, Scharpf D, et al. High interpatient variability
in response to mycophenolic acid maintenance therapy in patients with
ANCA-associated vasculitis. Nephrol Dial Transplant. 2015; 30
Suppl 1: i138-145.
- Chaigne B, Gatault P, Darrouzain F, et al. Mycophenolate mofetil in
patients with anti-neutrophil cytoplasmic antibody-associated
vasculitis: a prospective pharmacokinetics and clinical study.Clin Exp Immunol. 2014; 176(2): 172-179.
- Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate
GFR in children with CKD. J Am Soc Nephrol. 2009; 20(3):
629-637.
- Schwartz GJ, Schneider MF, Maier PS, et al. Improved equations
estimating GFR in children with chronic kidney disease using an
immunonephelometric determination of cystatin C. Kidney Int.2012; 82(4): 445-453
- Salvador CL, Tøndel C, Rowe AD, et al. Estimating glomerular
filtration rate in children: evaluation of creatinine- and cystatin
C-based equations. Pediatr Nephrol. 2019; 34(2): 301-311.
- Woillard JB, Bader-Meunier B, Salomon R, et al. Pharmacokinetics of
mycophenolate mofetil in children with lupus and clinical findings in
favour of therapeutic drug monitoring. Br J Clin Pharmacol.2014; 78(4): 867-876.
- Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics
in kidney disease: Fundamental principles. Clin J Am Soc
Nephrol . 2018;13(7): 1085-1095.
- Rong Y, Jun H, Kiang TKL. Population pharmacokinetics of mycophenolic
acid in paediatric patients. Br J Clin Pharmacol. 2021; 87(4):
1730-1757.
- Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of
mycophenolate sodium and comparison with the mofetil formulation in
stable kidney transplant recipients. Clin J Am Soc Nephrol.2007; 2(6): 1147-1155.
- Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with
mycophenolate mofetil bioavailability in kidney transplantation.Kidney Int. 2002; 62(3): 1060-1067.
- Rong Y, Mayo P, Ensom MHH, et al. Population Pharmacokinetics of
Mycophenolic Acid Co-Administered with Tacrolimus in
Corticosteroid-Free Adult Kidney Transplant Patients. Clin
Pharmacokinet. 2019; 58(11): 1483-1495.
- Romano-Aguilar M, Reséndiz-Galván JE, Medellín-Garibay SE, et al.
Population pharmacokinetics of mycophenolic acid in Mexican patients
with lupus nephritis. Lupus. 2020; 29(9): 1067-1077.
- Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a
filtration marker in glomerulopathic patients. Kidney Int.1985; 28(5): 830-838.
- Kidney Disease: Improving global outcomes (KDIGO) CKD work group.
KDIGO 2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. Kidney Int Suppl. 2013;
3(1): 1-150.
- Brou NA, Jacqz-Aigrain E, Zhao W. Cystatin C as a potential biomarker
for dosing of renally excreted drugs. Br J Clin Pharmacol .
2015; 80(1): 20-27.
- Barreto EF, Rule AD, Murad MH, et al. Prediction of the renal
elimination of drugs with cystatin C vs creatinine: A systematic
review. Mayo Clin Proc. 2019; 94(3): 500-514.
- Lu JJ, Chen M, Lv CL, et al. A population pharmacokinetics model for
vancomycin dosage optimization based on serum cystatin C. Eur J
Drug Metab Pharmacokinet. 2020; 45(4): 535-546.
- Downes KJ, Zane NR, Zuppa AF. Effect of Cystatin C on vancomycin
clearance estimation in critically Ill children using a population
pharmacokinetic modeling approach. Ther Drug Monit . 2020;
42(6): 848-855.
- Tan SJ, Cockcroft M, Page-Sharp M, et al. Population pharmacokinetic
study of ceftriaxone in elderly patients, using cystatin C-based
estimates of renal function to account for frailty. Antimicrob
Agents Chemother. 2020; 64(10): e00874-20.
- Björk J, Nyman U, Berg U, et al. Validation of standardized creatinine
and cystatin C GFR estimating equations in a large multicentre
European cohort of children. Pediatr Nephrol . 2019; 34(6):
1087-1098.
- Correa S, Pena-Esparragoza JK, Scovner KM, et al.
Myeloperoxidase and the risk of CKD
progression, cardiovascular disease, and death in the chronic rrenal
insufficiency cohort (CRIC) study. Am J Kidney Dis. 2020;
76(1): 32-41.
- Kronbichler A, Lee KH, Denicolò S, et al. Immunopathogenesis of
ANCA-Associated Vasculitis. Int J Mol Sci. 2020; 21(19): 7319.
- Couser WG, Johnson RJ. What is myeloperoxidase doing in
ANCA-associated glomerulonephritis? Kidney Int. 2015; 88(5):
938-940.
- Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic
drug metabolizing enzymes: hypothesis with implications for
personalized medicine. Drug Metab Dispos. 2015; 43(3): 400-410.
- Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside
conjugation of mycophenolic acid by human liver, kidney and intestinal
microsomes. Br J Pharmacol . 2001; 132(5): 1027-1034.
- Lamba V, Sangkuhl K, Sanghavi K, et al. PharmGKB summary: mycophenolic
acid pathway. Pharmacogenet Genomics . 2014; 24(1):73-79.
- Reséndiz-Galván JE, Romano-Aguilar M, Medellín-Garibay SE, et al.
Population pharmacokinetics of mycophenolic acid in adult kidney
transplant patients under prednisone and tacrolimus regimen. Eur
J Pharm Sci. 2020; 150: 105370.
- Knights KM, Rowland A, Miners JO. Renal drug metabolism in humans: the
potential for drug-endobiotic interactions involving cytochrome P450
(CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin
Pharmacol. 2013; 76(4): 587-602.
- Zhou X, Xie Y, Qi Q, et al. Disturbance of hepatic and intestinal
UDP-glucuronosyltransferase in rats with trinitrobenzene sulfonic
acid-induced colitis. Drug Metab Pharmacokinet. 2013; 28(4):
305-313.
- de Jong LM, Jiskoot W, Swen JJ, et al. Distinct effects of
inflammation on cytochrome P450 regulation and drug metabolism:
Lessons from experimental models and a potential role for
pharmacogenetics. Genes (Basel). 2020; 11(12): 1509.
- Richardson TA, Sherman M, Kalman D, et al. Expression of
UDP-glucuronosyltransferase isoform mRNAs during inflammation and
infection in mouse liver and kidney. Drug Metab Dispos. 2006;
34(3): 351-353.
- Kawase A, Norikane S, Okada A, et al. Distinct alterations in
ATP-binding cassette transporter expression in liver, kidney, small
intestine, and brain in adjuvant-induced arthritic rats. J Pharm
Sci. 2014; 103(8): 2556-2564.
- Diao L, Li N, Brayman TG, et al. Regulation of MRP2/ABCC2 and
BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes
exposed to inflammatory cytokines TNF-{alpha}, IL-6, and
IL-1{beta}. J Biol Chem . 2010; 285(41): 31185-31192.
- Evers R, Piquette-Miller M, Polli JW, et al. International Transporter
Consortium: Disease-associated changes in drug transporters may impact
the pharmacokinetics and/or toxicity of drugs: A white paper from the
international transporter consortium. Clin Pharmacol Ther .
2018;104(5): 900-915.
- Beunders R, Schütz MJ, van Groenendael R, et al. Endotoxemia-induced
release of pro-inflammatory mediators are associated with increased
glomerular filtration rate in humans in vivo. Front Med
(Lausanne) 2020;7: 559671.
- Udy AA, Roberts JA, Lipman J. Implications of augmented renal
clearance in critically ill patients. Nat Rev Nephrol. 2011;
7(9): 539-543.
- Barau C, Barrail-Tran A, Hemerziu B, et al. Optimization of the dosing
regimen of mycophenolate mofetil in pediatric liver transplant
recipients. Liver Transpl. 2011; 17(10): 1152-1158.
- Barau C, Mellos A, Chhun S, et al. Pharmacokinetics of mycophenolic
acid and dose optimization in children after intestinal
transplantation. Ther Drug Monit. 2017; 39(1): 37-42.
- Weber LT, Hoecker B, Armstrong VW, et al. Long-term pharmacokinetics
of mycophenolic acid in pediatric renal transplant recipients over 3
years posttransplant. Ther Drug Monit. 2008; 30(5): 570-575.
- Tellier S, Dallocchio A, Guigonis V, et al. Mycophenolic acid
pharmacokinetics and relapse in children with steroid-dependent
idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2016;
11(10): 1777-1782.